DK3489366T3 - Fremgangsmåder og produkter til produktion af manipulerede mammale cellelinier med forstærkede transgener - Google Patents

Fremgangsmåder og produkter til produktion af manipulerede mammale cellelinier med forstærkede transgener Download PDF

Info

Publication number
DK3489366T3
DK3489366T3 DK18211367.0T DK18211367T DK3489366T3 DK 3489366 T3 DK3489366 T3 DK 3489366T3 DK 18211367 T DK18211367 T DK 18211367T DK 3489366 T3 DK3489366 T3 DK 3489366T3
Authority
DK
Denmark
Prior art keywords
transgenes
amplified
products
methods
cell lines
Prior art date
Application number
DK18211367.0T
Other languages
English (en)
Inventor
Derek Jantz
James Jefferson Smith
Michael G Nicholson
Original Assignee
Prec Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prec Biosciences Inc filed Critical Prec Biosciences Inc
Application granted granted Critical
Publication of DK3489366T3 publication Critical patent/DK3489366T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0012Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • C12N9/003Dihydrofolate reductase [DHFR] (1.5.1.3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93Ligases (6)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y105/00Oxidoreductases acting on the CH-NH group of donors (1.5)
    • C12Y105/01Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
    • C12Y105/01003Dihydrofolate reductase (1.5.1.3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y603/00Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/01Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
    • C12Y603/01002Glutamate-ammonia ligase (6.3.1.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/04Phosphoric diester hydrolases (3.1.4)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK18211367.0T 2011-06-01 2012-06-01 Fremgangsmåder og produkter til produktion af manipulerede mammale cellelinier med forstærkede transgener DK3489366T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161492174P 2011-06-01 2011-06-01
EP12792301.9A EP2714936B1 (en) 2011-06-01 2012-06-01 Methods and products for producing engineered mammalian cell lines with amplified transgenes

Publications (1)

Publication Number Publication Date
DK3489366T3 true DK3489366T3 (da) 2020-02-24

Family

ID=47260412

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12792301.9T DK2714936T3 (da) 2011-06-01 2012-06-01 Fremgangsmåder og produkter til produktion af manipulerede mammale cellelinier med forstærkede transgener
DK18211367.0T DK3489366T3 (da) 2011-06-01 2012-06-01 Fremgangsmåder og produkter til produktion af manipulerede mammale cellelinier med forstærkede transgener

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK12792301.9T DK2714936T3 (da) 2011-06-01 2012-06-01 Fremgangsmåder og produkter til produktion af manipulerede mammale cellelinier med forstærkede transgener

Country Status (5)

Country Link
US (5) US20140179005A1 (da)
EP (3) EP3489366B1 (da)
DK (2) DK2714936T3 (da)
ES (2) ES2713529T3 (da)
WO (1) WO2012167192A2 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3494997T (pt) * 2012-07-25 2019-12-05 Massachusetts Inst Technology Proteínas de ligação a adn indutíveis e ferramentas de perturbação do genoma e aplicações destas
EP3858376B1 (en) 2014-03-12 2025-07-30 Precision Biosciences, Inc. Dystrophin gene exon deletion using engineered nucleases
MY185678A (en) 2014-04-10 2021-05-30 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Drug related transgene expression
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
EP3209785B1 (en) 2014-10-23 2019-07-31 Regeneron Pharmaceuticals, Inc. Novel cho integration sites and uses thereof
DK3289076T3 (da) 2015-05-01 2022-01-17 Prec Biosciences Inc Præcis sletning af kromosomale sekvenser in vivo
WO2017027291A1 (en) 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
AU2016321244B2 (en) 2015-09-08 2020-09-24 Precision Biosciences, Inc. Treatment of retinitis pigmentosa using engineered meganucleases
EP4446338A3 (en) 2015-09-23 2025-05-07 Pfizer Inc. Cells and method of cell culture
EP4108255A1 (en) 2015-10-05 2022-12-28 Precision Biosciences, Inc. Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
EP3940070A1 (en) 2015-10-05 2022-01-19 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
AU2016379393B2 (en) 2015-12-23 2023-01-05 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene
KR102479894B1 (ko) * 2016-03-30 2022-12-21 스파크 테라퓨틱스, 인코포레이티드 재조합 단백질 및/또는 바이러스 벡터 생산용 세포주
AU2017258304B2 (en) 2016-04-27 2019-07-04 University Of Puerto Rico 1,5-disubstituted 1,2,3-triazoles are inhibitors of Rac/Cdc42 GTPases
AU2017260426B2 (en) 2016-05-03 2023-08-31 Precision Biosciences, Inc. Engineered nucleases useful for treatment of hemophilia A
DK3526323T5 (da) 2016-10-14 2024-09-02 Prec Biosciences Inc Modificerede meganucleaser der er specifikke for en genkendelsessekvens i hepatitis b virusgenomet
JP7177076B2 (ja) * 2017-03-16 2022-11-22 ファイザー・インク チロシン原栄養性
CA3060112A1 (en) 2017-04-21 2018-10-25 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the pcsk9 gene
AU2018292526A1 (en) 2017-06-30 2020-01-16 Precision Biosciences, Inc. Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene
WO2019089913A1 (en) 2017-11-01 2019-05-09 Precision Biosciences, Inc. Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
IL304025A (en) 2018-04-12 2023-08-01 Prec Biosciences Inc Optimized engineered nucleases with specificity for the human T cell receptor alpha constant region gene
US20220090047A1 (en) 2018-12-21 2022-03-24 Precision Biosciences, Inc. Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
US20220195407A1 (en) 2019-05-07 2022-06-23 Precision Biosciences, Inc. Optimization of engineered meganucleases for recognition sequences
US20220273715A1 (en) * 2019-07-25 2022-09-01 Precision Biosciences, Inc. Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
CA3162622A1 (en) * 2019-11-25 2021-06-03 Baylor College Of Medicine Selective expansion of gene-targeted cells
FI4069729T3 (fi) 2019-12-06 2025-04-01 Prec Biosciences Inc Optimoidut muokatut meganukleaasit, joilla on spesifisyys tunnistussekvenssiä varten hepatiitti b -virusgenomissa
WO2021222238A1 (en) * 2020-04-27 2021-11-04 The Trustees Of The University Of Pennsylvania Compositions and methods for reducing nuclease expression and off-target activity using a promoter with low transcriptional activity
US20230183664A1 (en) 2020-05-11 2023-06-15 Precision Biosciences, Inc. Self-limiting viral vectors encoding nucleases
EP4150068A1 (en) 2020-05-12 2023-03-22 Precision BioSciences, Inc. Treatment of retinitis pigmentosa using improved engineered meganucleases
AU2021329403A1 (en) 2020-08-21 2023-05-04 Precision Biosciences, Inc. Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene
CA3172481A1 (en) 2020-11-12 2022-05-19 Precision Biosciences, Inc. Engineered meganucleases having specificity for recognition sequences in the dystrophin gene
CA3172161A1 (en) 2021-01-08 2022-07-14 James Jefferson Smith Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene
US20240141311A1 (en) 2021-04-22 2024-05-02 North Carolina State University Compositions and methods for generating male sterile plants
MX2023012484A (es) 2021-04-22 2024-02-15 Prec Biosciences Inc Meganucleasas diseñadas que se dirigen a los genomas mitocondriales humanos.
US12134776B2 (en) * 2021-10-06 2024-11-05 G&P Bioscience Co., Ltd. Development of optimized recombinant expression construct
MX2024004812A (es) 2021-10-19 2024-07-15 Prec Biosciences Inc Métodos de edición génica para el tratamiento de la deficiencia de alfa-1 antitripsina (aat).
WO2023070002A2 (en) 2021-10-19 2023-04-27 Precision Biosciences, Inc. Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
WO2025101946A1 (en) 2023-11-08 2025-05-15 Precision Biosciences, Inc. Polypeptide linkers for use in engineered meganucleases
WO2025233894A1 (en) 2024-05-09 2025-11-13 University Of Miami Engineered meganucleases that target human mitochondrial genomes
WO2026028165A1 (en) 2024-08-01 2026-02-05 Precision Biosciences, Inc. Engineered meganucleases having specificity for recognition sequences in the c9orf72 gene
CN119753013A (zh) * 2024-11-25 2025-04-04 杭州宏望医学检验实验室有限公司 一种适用于自身抗体检测的cho细胞株的构建及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156304A (en) 1990-12-20 2000-12-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for studying and treating a connective tissue of a mammalian host
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
US7338800B2 (en) * 2002-01-16 2008-03-04 Baylor College Of Medicine In vivo gene transfer
WO2009095742A1 (en) 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
EP2522723B1 (en) * 2003-01-28 2014-12-03 Cellectis Custom-made meganuclease and use thereof
DK2650365T3 (da) 2005-10-18 2016-12-05 Prec Biosciences Rationelt konstruerede meganukleaser med ændret sekvensspecificitet og dna-bindingsaffinitet
WO2007060495A1 (en) 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
WO2007137267A2 (en) * 2006-05-22 2007-11-29 Hiprocell, Llc Protein production using eukaryotic cell lines
WO2008059317A1 (en) 2006-11-14 2008-05-22 Cellectis Meganuclease variants cleaving a dna target sequence from the hprt gene and uses thereof
FR2910490B1 (fr) * 2006-12-20 2012-10-26 Lab Francais Du Fractionnement Lignee cellulaire a forte activite transcriptionnelle pour la production de proteines, notamment therapeutiques
CA2704383A1 (en) 2007-10-31 2009-05-07 James Jefferson Smith Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
WO2009076292A2 (en) 2007-12-07 2009-06-18 Precision Biosciences, Inc. Rationally-designed meganucleases with recognition sequences found in dnase hypersensitive regions of the human genome
WO2009114321A2 (en) * 2008-03-11 2009-09-17 Precision Biosciencs, Inc. Rationally-designed meganucleases for maize genome engineering
EP2352821B1 (en) * 2008-09-08 2016-11-23 Cellectis Meganuclease variants cleaving a dna target sequence from a glutamine synthetase gene and uses thereof
EP2180058A1 (en) * 2008-10-23 2010-04-28 Cellectis Meganuclease recombination system

Also Published As

Publication number Publication date
US9822381B2 (en) 2017-11-21
US20140179005A1 (en) 2014-06-26
US20220333137A1 (en) 2022-10-20
ES2713529T3 (es) 2019-05-22
EP2714936A4 (en) 2015-07-29
DK2714936T3 (da) 2019-03-25
EP2714936B1 (en) 2018-12-12
WO2012167192A2 (en) 2012-12-06
EP3489366B1 (en) 2019-12-25
ES2773891T3 (es) 2020-07-15
EP2714936A2 (en) 2014-04-09
EP3489366A1 (en) 2019-05-29
US20190249199A1 (en) 2019-08-15
US20180163233A1 (en) 2018-06-14
US20160017372A1 (en) 2016-01-21
WO2012167192A3 (en) 2014-05-08
EP3683319A1 (en) 2020-07-22

Similar Documents

Publication Publication Date Title
DK3489366T3 (da) Fremgangsmåder og produkter til produktion af manipulerede mammale cellelinier med forstærkede transgener
DK2872629T3 (da) Tm-forstærkede blokeringsoligonukleotider og lokkemidler til forbedret target-berigesle og reduceret off-target-udvælgelse
DK3045187T3 (da) Injektor og fremgangsmåde til samling
DK2756073T3 (da) Manipuleret væv til in vitro-forskningsanvendelser, anordninger deraf og fremgangsmåder til fremstilling deraf
DK3468197T3 (da) Fremgangsmåde til interforudsigelse og indretning dertil
DK3257943T3 (da) Fremgangsmåder og vektorer til celleimmortalisering
EP2880054A4 (en) HLA-G-MODIFIED CELLS AND METHOD
DK3482765T3 (da) Langtidsvirkende væksthormon og fremgangsmåder til produktion deraf
DK3308641T3 (da) Immundeficient genmodificeret gnaver og fremgangsmåder til anvendelse deraf
DK2625253T3 (da) System og fremgangsmåde til ristning af biomasse
PL3863288T3 (pl) Sposoby intra-predykcji i środek nośnikowy
DK2678283T3 (da) Vanadiumbaserede frittematerialer og fremgangsmåder til deres fremstilling
DK2794907T3 (da) Fremgangsmåder og materialer til vurdering af tab af heterozygositet
DK2528180T3 (da) Metoder og systemer til jævnstrøms-energitransmission
DK2794850T3 (da) Bioteknologisk produktion af alkoholer og derivater deraf
DK2506416T3 (da) System og fremgangsmåde til strømkonvertering
DK3489685T3 (da) Signalforstærkning i sidestrømning og tilsvarende immunoassays
DK2867600T3 (da) System og fremgangsmåde til carbondioxidopfangning og -deponering
DK3421051T3 (da) Fremgangsmåder til glycokonjugering og sammensætninger
DK2758349T3 (da) Vanadiumbaserede frittematerialer og fremgangsmåder til fremstilling heraf
DK2915064T3 (da) Fremgangsmåde til at indikere tilstedeværelsen af gashydrat og overfladegas i et undervandsmiljø
DK2521221T4 (da) Høreanordning og fremgangsmåde
DK2744456T3 (da) Forbedringer ved eller i forbindelse med proteser og ortoser
DK2428068T3 (da) Fremgangsmåder og anordninger til understøttelse af DTX
DK3415157T3 (da) N-acyldipeptidderivater og anvendelser deraf